Back to BAX Stock Lookup

Baxter Int'l (BAX) – Press Releases

Feb 23, 2015 09:00 AM Baxter Selects Bannockburn, Ill., Facility as Location for Baxalta Global Headquarters
Feb 19, 2015 04:15 PM Baxter to Present at Barclay’s Global Healthcare Conference
Feb 17, 2015 09:00 AM Baxter Declares Quarterly Dividend
Feb 12, 2015 04:30 PM Baxter Provides Progress Update on Gene Therapy Program, Including Phase I/II Clinical Trial of BAX 335, Investigational Gene Therapy Treatment for Hemophilia B
Feb 11, 2015 09:00 AM Baxter Presents Additional Data from Pivotal Study of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based on ADVATE for Hemophilia A
Feb 10, 2015 04:15 PM Baxter to Present at Cowen & Company’s 35th Annual Health Care Conference
Jan 29, 2015 07:00 AM Baxter’s Fourth Quarter Financial Results Exceed Expectations
Jan 21, 2015 01:41 AM PharmaEngine Announces Phase 2 PEPCOL Study Presented at the 2015 ASCO GI of PEP02 (MM-398) in Combination with 5-FU/LV in Unresectable Metastatic Colorectal Cancer
Jan 20, 2015 09:00 AM Baxter Receives FDA Approval for PHOXILLUM Solution for Electrolyte Management During Continuous Renal Replacement Therapy
Jan 20, 2015 08:00 AM Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
Jan 19, 2015 04:00 AM PharmaEngine Announces Expanded Analyses of Phase 3 MM-398 NAPOLI-1 Study Presented at the 2015 ASCO GI Substantiate the Positive Results of MM-398 in Combination with 5-FU/LV
Jan 15, 2015 09:00 AM Palmetto Health in Columbia, South Carolina, Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service
Dec 22, 2014 09:00 AM Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment for Von Willebrand Disease
Dec 18, 2014 03:15 PM Baxter to Present at 33rd Annual J.P. Morgan Healthcare Conference
Dec 17, 2014 04:15 PM Baxter International Fourth Quarter 2014 Financial Results Conference Call
Dec 15, 2014 09:00 AM Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
Dec 10, 2014 05:15 PM Baxter Announces Filing of Form 10 Registration Statement in Connection with Planned Spin off of Biopharmaceuticals Business
Dec 9, 2014 09:00 AM Baxter’s Culture of Community Engagement and Inclusion Recognized by Leading Organizations
Dec 4, 2014 08:00 AM Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research

Back to BAX Stock Lookup